Qyuns Therapeutics Co., Ltd. (HKG:2509)

Market Cap	3.70B -44.0%
Revenue (ttm)	1.18B +219.8%
Net Income	630.46M
EPS	2.80
Shares Out	223.37M
PE Ratio	5.91
Forward PE	13.78
Dividend	n/a
Ex-Dividend Date	n/a

Volume	62,000
Open	16.00
Previous Close	16.74
Day's Range	16.00 - 16.56
52-Week Range	13.21 - 31.48
Beta	1.42
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 19, 2026

About Qyuns Therapeutics

Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, engages in the research and development of biologic therapies for autoimmune and allergic diseases in China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor, which completed Phase III clinical trial for the treatment of ankylosing spondylitis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra that is in Phase III clinical trial for treating prurigo nodularis. The company also develops QX001S, which is an IL-12/L-23p40 inhibitor for psoriasis unde...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 353
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2509

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 22, 2026

Data Sources Report a data error